Veracyte is trading 4% down now at $42.10 after hotter-than-expected producer inflation and reduced expectations for near-term Federal Reserve easing.

  • The S&P 500, Nasdaq Composite, and Dow Jones are each down more than 0.5%, pressuring rate-sensitive growth stocks.
  • No clear negative company-specific announcement was identified.
  • Recent coverage included UBS initiating coverage with a Buy rating and a $65 target.